rs72648250
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_001267550.2(TTN):c.93166C>T(p.Arg31056Ter) variant causes a stop gained change. The variant allele was found at a frequency of 0.00000547 in 1,461,598 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Synonymous variant affecting the same amino acid position (i.e. R31056R) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_001267550.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TTN | NM_001267550.2 | c.93166C>T | p.Arg31056Ter | stop_gained | 339/363 | ENST00000589042.5 | NP_001254479.2 | |
TTN-AS1 | NR_038272.1 | n.2043+6099G>A | intron_variant, non_coding_transcript_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TTN | ENST00000589042.5 | c.93166C>T | p.Arg31056Ter | stop_gained | 339/363 | 5 | NM_001267550.2 | ENSP00000467141 | P1 | |
TTN-AS1 | ENST00000659121.1 | n.416+24824G>A | intron_variant, non_coding_transcript_variant |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000403 AC: 1AN: 248360Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134696
GnomAD4 exome AF: 0.00000547 AC: 8AN: 1461598Hom.: 0 Cov.: 34 AF XY: 0.00000413 AC XY: 3AN XY: 727076
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
not provided Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Sep 19, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 23, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Also reported as Arg21991* due to alternate nomenclature; This variant is associated with the following publications: (PMID: 25589632, 23975875, 33106378, 24119082, 31317183, 31514951, 36264615, 34731015, 36396199, 36761691, 35877578, 22335739) - |
TTN-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 11, 2024 | The TTN c.93166C>T variant is predicted to result in premature protein termination (p.Arg31056*). This variant occurs within the A-band region of the titin protein, in which truncating TTN variants have been found more frequently in dilated cardiomyopathy patients than in controls (Herman et al. 2012. PubMed ID: 22335739). RNAseq studies from heart tissue indicate this exon is commonly included in TTN mRNA transcripts (PSI of 100%, Roberts et al. 2015. PubMed ID: 25589632; https://cardiodb.org/titin/titin_transcripts.php). TTN truncating variants are reported in 1-2% of presumably healthy individuals and occur more frequently in exons with low PSI values, indicating that this variant is more likely to be disease causing (Herman et al. 2012. PubMed ID: 22335739; Roberts et al. 2015. PubMed ID: 25589632). This variant is also known as c.88242C>T (p.Arg29415*) and has been reported in individuals with dilated cardiomyopathy (for examples, see Supplementary Appendix Table 6, Herman et al. 2012. PubMed ID: 22335739; Franaszczyk et al. 2017. PubMed ID: 28045975). This variant is reported in 0.00089% of alleles in individuals of European (Non-Finnish) descent in gnomAD. In addition, truncating TTN variants have been associated with autosomal recessive titinopathies (Ceyhan-Birsoy et al. 2013. PubMed ID: 23975875, Savarese et al. 2020. PubMed ID: 32778822, Oates et al. 2018. PubMed ID: 29691892; Bryen et al. 2020. PubMed ID: 31660661), with presentations including muscle weakness. Therefore, this variant is interpreted as pathogenic for recessive and dominant TTN-related disorders. - |
Autosomal recessive limb-girdle muscular dystrophy type 2J;C1858763:Dilated cardiomyopathy 1G Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 13, 2023 | This sequence change creates a premature translational stop signal (p.Arg31056*) in the TTN gene. While this is not anticipated to result in nonsense mediated decay, it is expected to create a truncated TTN protein. This variant is present in population databases (rs72648250, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with dilated cardiomyopathy (PMID: 22335739, 28045975). It has also been observed to segregate with disease in related individuals. This variant is also known as p.R29415*. ClinVar contains an entry for this variant (Variation ID: 223326). This variant is located in the A band of TTN (PMID: 25589632). Truncating variants in this region are significantly overrepresented in patients affected with dilated cardiomyopathy (PMID: 25589632). Truncating variants in this region have also been reported in individuals affected with autosomal recessive centronuclear myopathy (PMID: 23975875). For these reasons, this variant has been classified as Pathogenic. - |
Dilated cardiomyopathy 1G Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | Cardiogenetics and Myogenetics Molecular and Cellular Functional Unit, Aphp Sorbonne University-Hopital Pitie Salpetriere | Jan 06, 2024 | - - |
Autosomal recessive limb-girdle muscular dystrophy type 2J;C1838244:Tibial muscular dystrophy;C1858763:Dilated cardiomyopathy 1G;C1861065:Hypertrophic cardiomyopathy 9;C1863599:Myopathy, myofibrillar, 9, with early respiratory failure;C2673677:Early-onset myopathy with fatal cardiomyopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Aug 12, 2021 | - - |
Primary familial dilated cardiomyopathy Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute | - | - - |
Primary dilated cardiomyopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | research | Cardiovascular Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust | Oct 08, 2014 | This TTN truncating variant (TTNtv) was identified in one individual in this cohort and is located in an exon that is highly expressed in the heart. In the seven cohorts assessed, TTNtv were found in 14% of ambulant DCM, 22% end-stage or familial DCM, and 2% controls. Heterozygous nonsense, frameshift and canonical splice-disrupting variants found in constitutive and other highly utilised exons are highly likely to be pathogenic when identified in individuals with phenotypically confirmed DCM. TTNtv found incidentally in healthy individuals (excluding familial assessment of DCM relatives) are thought to have low penetrance, particularly when identified in exons that are not constitutively expressed in the heart. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | May 06, 2022 | The p.R21991* pathogenic mutation (also known as c.65971C>T), located in coding exon 166 of the TTN gene, results from a C to T substitution at nucleotide position 65971. This changes the amino acid from an arginine to a stop codon within coding exon 166. This variant is located in the A-band region of the N2-B isoform of the titin protein, and is constitutively expressed in TTN transcripts (percent spliced in or PSI 100%). This truncating alteration has been reported in unrelated individuals with dilated cardiomyopathy (DCM) and has been reported to segregate with disease in families (Herman DS et al. N Engl J Med. 2012;366(7):619-28; Franaszczyk M. PLoS ONE. 2017;12(1):e0169007). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. While truncating variants in TTN are present in 1-3% of the general population, truncating variants in the A-band are the most common cause of dilated cardiomyopathy (DCM) (Herman DS et al. N. Engl. J. Med., 2012 Feb;366:619-28; Roberts AM et al. Sci Transl Med, 2015 Jan;7:270ra6). TTN truncating variants encoded in constitutive exons (PSI >90%) have been found to be significantly associated with DCM regardless of their position in titin (Schafer S et al. Nat. Genet., 2017 01;49:46-53). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at